London, UK (December 2, 2010) SAGE has extended its suite of Therapeutic Advances journals with the launch of a further two titles: Therapeutic Advances in Drug Safety, and Therapeutic Advances in Hematology.
Therapeutic Advances in Drug Safety covers novel and controversial aspects pertaining to the safe use of drugs in different age and ethnic patient groups, drug safety, therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics and regulation.
Therapeutic Advances in Hematology is for all professionals concerned with research and practice of hematology and is a forum for publishing original research and reviews in this area including research across all areas of hematology, including all of the malignant myeloid and lymphoid disorders (leukemia, myeloproliferative disorders, myelodysplasia, myeloma, lymphoma), red cell and platelet disorders, including transfusion medicine and clotting disorders, and any other relevant topic in the field.
Both international in scope, the journals follow the highly successful format of the existing nine Therapeutic Advances titles, offering rapid peer review and publication, with manuscripts published online within seven weeks of acceptance. Each journal publishes six issues per year and will be freely available on the award-winning SAGE Journals Online platform for the first three years of publication.
"We are delighted to expand the Therapeutic Advances series to cover these vital areas of medical research and practice" said Tessa Picknett, Associate Director and Publisher, STM Journals. "Our continuing aim is to rapidly publish high-quality clinically relevant, peer-reviewed original research and reviews, written by highly respected authors for busy specialists and other health professionals."